Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Business & Industry
- Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
- U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer
- Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
- Roche and Illumina partner to broaden patient access to genomic testing
- Amgen announces global diagnostic collaborations
Research & Development
- Dozens of non-oncology drugs can kill cancer cells
- B cells linked to effective cancer immunotherapy
- Edible 'security tag' to protect drugs from counterfeit
- Women's blood vessels age faster than men's
- Exosomes promote remarkable recovery in stroke
- Vitamin B6, leukemia's deadly addiction
- Plant-derived SVC112 hits cancer stem cells, leaves healthy cells alone
Conferences & Events
- Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
- SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
- SMi's 4th Annual 3D Cell Culture
- Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
- RNA Therapeutics Conference and Focus Day
- CPhI Worldwide announces the winners of the 16th Pharma Awards
- CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023
Regulatory Affairs
- FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
- FDA approves new treatment for adults with migraine
- FDA approves first generics of Eliquis
- FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
- FDA approves new type of therapy to treat advanced urothelial cancer